• Skip to main content
Search
  • Home
  • Services
      • Behavioral Health
      • Bloodless Medicine
      • Brain & Spine
      • Cancer Care
      • Ear, Nose and Throat
      • Emergency Care
      • Senior Health
      • Heart & Vascular Care
      • Home Health Care
      • Immediate Care
      • Medical Imaging
      • Minimally Invasive Surgery
      • Orthopedics
      • Pregnancy & Childbirth
      • Primary Care
      • Rehabilitation Services
      • Weight Loss Surgery
      • Wound Healing & Care
      • Women's Health
  • Doctors
      • Find a Primary Care Doctor
      • Find a Doctor
      • Physician Referral
      • Practices:

        Baptist Primary Care
      • Baptist AgeWell
      • Baptist Behavioral Health
      • Baptist Endocrinology
      • Baptist ENT Specialists
      • Baptist Heart Specialists
      • Baptist Infectious Diseases
      • Baptist MD Anderson Cancer Physicians
      • Baptist Neurology
      • Baptist Pediatrics
      • Baptist Pulmonary Specialists (Nassau)
      • Baptist Rheumatology
      • Baptist Urology Group (Nassau)
      • Jacksonville Orthopaedic Institute
      • Lyerly Neurosurgery
  • Locations
    • Our Hospitals:

      • Baptist Medical Center Jacksonville
      • Baptist Medical Center South
      • Baptist Medical Center Beaches
      • Baptist Medical Center Nassau
      • Baptist Heart Hospital
      • Wolfson Children's Hospital

      Emergency Rooms (ER):

      • All ER Locations

      Imaging:

      • By Location

      • Imaging Center Locations
      • By Service

      • MRI
      • Bone Density
      • Screening Mammography
      • Diagnostic Mammography
      • Ultrasound
      • Vascular Ultrasound
      • CT Scan
      • PET Scan
      • Nuclear Medicine
      • X-Ray

      Urgent Care Locations:

      • Baptist Health Clinics at Walgreens
      • CareSpot Urgent Care

      Outpatient Locations:

      • AgeWell Center for Senior Health
      • Baptist Clay Medical Campus
      • Baptist MD Anderson Cancer Center
      • Baptist Neurodiagnostic Center
      • Baptist North Medical Campus
      • Heart and Vascular Testing Centers
      • Hill Breast Center
      • Infusion Center
      • Pharmacy
      • Rehabilitation Centers
      • Robotic Spine Surgery
      • Sleep Centers
      • Stroke and Cerebrovascular Center
      • Surgery Centers
      • Wound Care

      Health & Wellness:

      • 4her Wellness Resources for Women
      • JCA Wellness Connexion
      • Y Healthy Living Centers
  • Patient Info
      • Billing & Insurance Information
      • Insurance Plans Accepted
      • Cost Estimate Request
      • Financial Assistance Program
      • My Baptist Connect (Patient Portal)
      • Medical Records
      • Classes and Events
      • Clinical Trials
      • Tell Us What You Think
  • Health Library
      • Diseases and Conditions
      • Symptoms
      • Tests
      • Surgeries and Procedures
      • Injuries
      • Nutrition
      • Poison
      • Drug Information
      • Drug Images
      • Health News
      • Video Library
  • About Us
      • Administration
      • Awards & Honors
      • Careers
      • Provider Opportunities
      • Baptist MD Anderson Provider Opportunities
      • Spiritual Care
      • Social Responsibility
      • Community Health Needs Assessment (CHNA)
      • Corporate Wellness (PATH)
      • Volunteering
      • Newsroom
  • Juice
      • Health News Overview:

      • Aging Well
      • Brain, Spine & Nerve
      • Cancer
      • Child Health
      • Community Health
      • Diabetes
      • Ear, Nose & Throat
      • Heart & Vascular
      • Lungs, Breathing & Sleep
      • Mental Health
      • Orthopedics, Bones & Muscles
      • Pregnancy & Childbirth
      • Primary Care
      • Wellness
      • Women's Health
      • Men's Health
  1. Home
  2. Health Library
  3. Health News
  4. FDA Poised to Approve Ketamine-Like Drug to Ease Depression

FDA Poised to Approve Ketamine-Like Drug to Ease Depression

TUESDAY, March 5, 2019 (HealthDay News) -- The U.S. Food and Drug Administration could give its approval this week to esketamine -- a relative of the "club drug" and anesthetic ketamine -- against severe depression.

If that approval comes, it could be the first new class of medicines approved for years against an illness that plagues millions of Americans.

Approval couldn't be too soon for Jen Godfrey, who couldn't shake the "deep cloud" that lingered even after she found an antidepressant she could tolerate.

Then a string of stressors hit -- five years of fertility treatment and an 80-pound weight gain during pregnancy that left her with persistent pain, a close relative's suicide, another who went missing, and her own divorce. It was all too much for Godfrey, a recovering alcoholic with a family history of depression.

"The life stuff just had a gravitational pull," said the stay-at-home mom from Reno, Nev, who's in her mid-40s. "I just thought: I don't drink, I'm a good friend, a good mother, a good spouse -- I should be a lot happier."

Godfrey's search for relief pointed her to an unapproved and costly treatment for depression -- ketamine. An animal anesthetic best known as the addictive party drug "Special K," ketamine was approved for use as a human anesthetic in 1970. It's often used in emergency care to sedate kids and patients with breathing problems.

Low, intravenous doses have been found to boost mood and curb suicidal thoughts, but the FDA has not approved it as a treatment for depression. And the American Psychiatric Association (APA) warns patients about the potential for abuse and the lack of large, long-term studies of its effectiveness.

Even so, ketamine clinics like the one now treating Godfrey are springing up across the United States, prescribing the drug for "off-label" use against depression.

"The lack of information [on ketamine] is really quite dramatic when you look at the proliferation of use in certain communities," said former APA President Dr. Alan Schatzberg. He helped write an APA statement about ketamine urging caution.

A safer alternative?

Esketamine, the new drug seeking FDA approval, is meant to be a much safer version of ketamine.

Speaking this week with National Public Radio, Courtney Billington, president of Janssen Neuroscience, said esketamine will be marketed under the brand name Spravato.

Billington said numerous restrictions on Spravato's use will be put in place.

First, only patients who have failed at least two other antidepressants will be eligible for a prescription, and "Spravato will not be dispensed directly to a patient to take it home. It will only be available in approved and certified treatment centers," he said.

Also, unlike ketamine, "the amount of active ingredient that's in this product is at a very, very low dose," Billington told NPR.

That's important, because ketamine can trigger disturbing effects such as hallucinations and dissociation, a sense of being disconnected from one's body and the world. Spravato shouldn't carry those risks, Billington said.

In the meantime, clinics offering generic ketamine continue to do business.

It's not even clear exactly how ketamine works to improve mood, Schatzberg said.

One common theory is that it affects the brain's response to the neurotransmitter glutamate. Neurotransmitters are chemicals that send signals from one part of the brain to another and from the brain to the body. Essentially, the thinking goes, ketamine rewires the brain.

But Schatzberg, a professor of psychiatry and behavioral sciences at Stanford University, was part of a small study published online in The American Journal of Psychiatry. It suggested another explanation -- that ketamine somehow activates opioid receptors in the brain.

"We could be exposing people to untoward consequences from a drug that works through an opioid mechanism," he said. With an opioid addiction crisis in full swing across the United States, "we need to study [ketamine] more," he added.

When other treatments have failed

Dr. Robert Watson, Godfrey's doctor at Sierra Ketamine Clinics in Reno, agreed that more study is needed. He thinks researchers could learn much from clinics like his that offer ketamine as an off-label depression treatment.

Watson said he's seen the drug help many patients whose depression hasn't responded to other medications and/or talk therapy.

Since opening over a year ago, his clinic has treated about 500 patients -- roughly 75 percent of them for chronic depression. It also uses ketamine to treat some other mental health problems, including post-traumatic stress, as well as chronic pain.

For depression, patients get four to six infusions, twice a week. Because the treatment is not FDA-approved, insurance rarely covers the cost, which averages $500 per dose. Patients go home with ketamine lozenges or nasal sprays to prolong the benefits. Some have gone six months or more without needing a booster infusion, Watson said.

Family members often notice a dramatic turnaround in mood after a patient's first 45-minute infusion, he said. Other patients only see the benefit after several IV doses. Most find treatment peaceful and relaxing, though it causes nausea in some, Watson said, and some dislike the feeling of being disconnected from their body and the world.

But he said he's seen no issues with abuse at the low and infrequent doses patients receive.

"There's still a lot we don't know, but even with what we don't know, it's proved to be the most efficacious and rapid-acting drug that we've ever seen for depression," Watson said. "It definitely needs to be looked at."

A 'game-changer'

Godfrey said ketamine has been nothing short of a miracle for her. Before that, she had tried a series of antidepressants before finding one that helped a bit, and everything from acupuncture to yoga and meditation. But her gloom and pain never seemed to go away.

During her first ketamine infusion, however, Godfrey felt an almost immediate sense of warmth and well-being, she said. Her second dose brought "the presence of a being that said 'everything is going to be OK.'

"I didn't even realize how heavy the weight had gotten until it was totally lifted," Godfrey said. "Immediately following [an infusion], you have about 10 solid hours of no pain whatsoever, and it cut down my actual pain by about 75 percent in a lasting way."

She continues to take the antidepressant Lexapro (escitalopram) and sees a psychologist about once a month. When she needs it, she puts a ketamine lozenge under her tongue at bedtime, and she drifts off to sleep.

"I did not think that anything with this much relief and promise would come along in my lifetime, let alone now," Godfrey said. "It's a game-changer."

More information

The U.S. National Institutes of Health has more about ketamine.

SOURCES: Jen Godfrey, Reno, Nev.; Alan Schatzberg, M.D., professor, psychiatry and behavioral sciences, Stanford University, Stanford, Calif., and former president, American Psychiatric Association; Robert Watson, M.D., owner, Sierra Ketamine Clinics, Reno, Nev.; "Ketamine," Steven Rosenbaum and Jorge Palacios, Oct. 27, 2018, NCBI Bookshelf, U.S. National Institutes of Health; National Public Radio

Daily Health and Medical News

  • Babies May 'See' Light While in the Womb
    December 03, 2019

  • Uncontrolled Asthma a Danger to Pregnant Women, Babies
    December 03, 2019

  • Are E-Scooters a Quick Ticket to the ER?
    December 03, 2019

  • Taking Several Prescription Drugs May Trigger Serious Side Effects
    December 03, 2019

  • AHA News: Vegan Diet May Decrease Heart Disease, Stroke Risk in African Americans
    December 03, 2019

© Copyright 2019 | All Rights Reserved

If you speak another language, assistance services
free of charge, are available to you.

Baptist Health Facebook Baptist Health Twitter Baptist Health on LinkedIn Baptist Health on Instagram Baptist Health on Youtube
Physician Login | Application Login | Employee Login
Quality Measures | Privacy | Non-Discrimination | Comments | Site Map